Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 3/20 | 0.30 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134356 | 0.78 | — | — | |
| SCHEMBL6782280 | 0.78 | — | — | |
| Toluene SCHEMBL28143362 | 0.71 | TSHR (0.61) | LMNATSHRALOX12ACHEMAPK1 | |
| Toluene SCHEMBL719989 | 0.71 | ACHE (0.61) | LMNATSHRALOX12ACHEKCNN4 | |
| Toluene SCHEMBL6431364 | 0.71 | ACHE (0.61) | LMNATSHRALOX12ACHEMAPK1 | |
| Toluene SCHEMBL3958941 | 0.69 | ACHE (0.79) | LMNATSHRALOX12ACHEKCNN4 | |
| Toluene SCHEMBL6068472 | 0.69 | ACHE (0.58) | LMNATSHRALOX12ACHEMAPK1 | |
| Toluene SCHEMBL7309310 | 0.69 | TSHR (0.58) | LMNATSHRALOX12ACHEMAPK1 | |
| Toluene SCHEMBL11594422 | 0.69 | TSHR (0.58) | LMNATSHRALOX12ACHEMAPK1 | |
| Toluene SCHEMBL28783234 | 0.67 | ACHE (0.73) | LMNATSHRALOX12ACHEKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102211-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | Alantos Pharmaceuticals Holding, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | NOLTE BERT | 2008-07-24 | — | — | US | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176870-A1 | Heterobicyclic metalloprotease inhibitors | ADAM17, ADAM8, ADAM10 | LMNA 2457/4885TSHR 4588/4885ALOX12 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.